Spanish Biotech Database

GYEONGGI, South Korea, Feb. 14, 2019 /PRNewswire/ -- SK Biopharmaceuticals and Arvelle Therapeutics GmbH today announced that they have entered into an exclusive licensing agreement for Arvelle to develop and commercialize cenobamate in Europe. Cenobamate is a novel, small molecule investigational... Read more ››

By: PR Newswire Association LLC. - 14 Feb 2019

Singapore Health Sciences Authority Approves Biktarvy(R) (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection

SINGAPORE, Feb. 14, 2019 /PRNewswire/ -- Gilead Sciences, Inc. today announced that the Singapore Health Sciences Authority has approved Biktarvy® (bictegravir 50mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg; BIC/FTC/TAF), a once-daily single tablet regimen (STR) for the treatment of HIV-1... Read more ››

By: PR Newswire Association LLC. - 14 Feb 2019

Trading in Novo Nordisk shares by board members, executives and associated persons on 12 February 2019

By: Nasdaq / GlobenewsWire - 13 Feb 2019

Information concerning the total number of voting rights and shares

By: Nasdaq / GlobenewsWire - 12 Feb 2019

Sanofi appoints Ameet Nathwani Chief Digital Officer

By: Nasdaq / GlobenewsWire - 12 Feb 2019

Novo Nordisk A/S - Share repurchase programme

By: Nasdaq / GlobenewsWire - 11 Feb 2019

Advanced Accelerator Applications Announces Health Canada Approval for Lutathera™, a Treatment for Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)¹

By: Nasdaq / GlobenewsWire - 07 Feb 2019

Related companies: Advanced Accelerator Applications Canada, Inc. | Advanced Accelerator Applications SA | Advanced Accelerator Applications Ibérica S.L. | Advanced Accelerator Applications USA, Inc.

Grifols Receives FDA Approval for Procleix Babesia Assay for Donor Screening on Procleix Panther System

BARCELONA, Spain, Feb. 7, 2019 /PRNewswire/ -- Grifols, a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, announced today that the U.S. Food and Drug Administration (FDA) approved the Procleix Babesia assay, a qualitative... Read more ››

By: PR Newswire Association LLC. - 07 Feb 2019

Related companies: Grifols International, S.A

ORYZON Announces Publication of a relevant paper for the therapeutic development of Iadademstat (ORY-1001) in Small Cell Lung Cancer (SCLC)

By: Nasdaq / GlobenewsWire - 06 Feb 2019

Related companies: Oryzon Genomics, S.A.

Sanofi: FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)

By: Nasdaq / GlobenewsWire - 06 Feb 2019

Lundbeck realized 8% growth in revenue (local currencies) and 48% growth in EPS in 2018

By: Nasdaq / GlobenewsWire - 05 Feb 2019

« 1 2 3 4 5 6 7 8 »

Looking for companies outside of Spain?

Browse our global Life Sciences lead sourcing platform Biotechgate for company information, product pipelines, licensing opportunities, management details and much more.

Partners

Upcoming Life Sciences Events

September 2019
- Boston: 9th Annual American Drug Delivery & Formulation Summit
- Malmo: NLS Days 2019
- Boston: Redefining Early Stage Investments (RESI)

See Events »

Add an Event »

Latest company news

Janssen Korea Ltd. and Johnson & Johnson Innovation Announce Launch of Seoul Innovation QuickFire Challenge in Smart Healthcare in Collaboration with Seoul Metropolitan Government and Korea Health Industry Development Institute
18 Jul 2019 (PR Newswire Association LLC.)

ORYZON Presents Data From ETHERAL Phase IIa Trial at the 2019 Alzheimer's Association International Conference in Los Angeles
16 Jul 2019 (Nasdaq / GlobenewsWire)

Novo Nordisk A/S – Share repurchase programme
15 Jul 2019 (Nasdaq / GlobenewsWire)

News in the Life Sciences Industry

Novo Nordisk receives US FDA approval of ESPEROCT® (turoctocog alfa pegol, N8-GP)

Novo Nordisk A/S - Share repurchase programme

Lundbeck increases its share capital by 5,631 shares (0.0028 % of outstanding shares) as a result of exercise of employee warrants

ORYZON Reports Financial Results and Corporate Update for the 4th Quarter and Year Ended December 31, 2018

Annual General Meeting in ALK-Abelló A/S on 13 March 2019

Lundbeck and Otsuka report phase III data evaluating brexpiprazole for the treatment of manic episodes associated with bipolar I disorder

SK Biopharmaceuticals and Arvelle Therapeutics Announce Agreement to Develop and Commercialize Cenobamate in Europe

Singapore Health Sciences Authority Approves Biktarvy(R) (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection

Trading in Novo Nordisk shares by board members, executives and associated persons on 12 February 2019

Information concerning the total number of voting rights and shares

Sanofi appoints Ameet Nathwani Chief Digital Officer

Novo Nordisk A/S - Share repurchase programme

Advanced Accelerator Applications Announces Health Canada Approval for Lutathera™, a Treatment for Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)¹

Grifols Receives FDA Approval for Procleix Babesia Assay for Donor Screening on Procleix Panther System

ALK releases its annual report 2018

Sanofi delivers 2018 business EPS growth of 5.1% at CER

Sanofi's Board of Directors notes the resignation of Christian Mulliez and co-opts Christophe Babule as Director

ORYZON Announces Publication of a relevant paper for the therapeutic development of Iadademstat (ORY-1001) in Small Cell Lung Cancer (SCLC)

Sanofi: FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)

Lundbeck realized 8% growth in revenue (local currencies) and 48% growth in EPS in 2018

Looking for companies outside of Spain?

Partners

Upcoming Life Sciences Events

Latest company news